Rituximab biosimilar - Nanogen Biopharmaceutical

Drug Profile

Rituximab biosimilar - Nanogen Biopharmaceutical

Latest Information Update: 14 Mar 2014

Price : $50

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Chronic lymphocytic leukaemia; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis

Most Recent Events

  • 14 Mar 2014 Early research in Wegener's granulomatosis in Vietnam (IV)
  • 14 Mar 2014 Early research in Rheumatoid arthritis in Vietnam (IV)
  • 14 Mar 2014 Early research in Non-Hodgkin's lymphoma in Vietnam (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top